BofA Securities has lowered its price target for Agios Pharmaceuticals from $50 to $48 following the company's Q3 2026 earnings report. This adjustment indicates a slightly less optimistic valuation from the analyst firm, which could exert minor downward pressure on the stock in the short term.
BofA Securities adjusted its price target for Agios Pharmaceuticals to $48 from $50 on November 6, 2026. This action directly followed the company's third-quarter 2026 earnings report, suggesting that the analyst firm's updated valuation assessment incorporated new information from the earnings. While a price target reduction is generally a negative signal, this specific adjustment is relatively small (4% decrease). For traders, this is a minor negative catalyst in the short term, potentially leading to slight downward pressure or increased scrutiny on AGIO. The long-term implications depend more on the underlying reasons for the valuation change, which are not detailed in this filing, but it signals a slightly less favorable outlook from BofA.